Table 5.
Changes of eGFR (ml/min/1.73m2) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated
| Crude model | Adjusted for baseline age, gender, ethnicity | |||
|---|---|---|---|---|
| Coefficient β (95% CI) | p-value | Coefficient β (95% CI) | p-value | |
| (Intercept) | 85.813 (84.676, 86.950) | < 0.001 | 93.974 (90.352, 97.595) | < 0.001 |
| Group | 0.991 (− 1.085, 3.068) | 0.349 | 1.76 (− 0.286, 3.805) | 0.092 |
| Time | − 0.014 (− 0.050, 0.022) | 0.449 | −0.016 (− 0.051, 0.019) | 0.379 |
| Group x Time a | −0.034 (− 0.094, 0.027) | 0.278 | −0.033 (− 0.092, 0.026) | 0.268 |
a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. CI confidence interval; eGFR estimated glomerular filtration rate; TDF Tenofovir disoproxil fumarate